JCI: New Discovery! A Parkinson's disease drug itraphylline may be expected to reduce the side effects of cisplatin chemotherapy!

Cisplatin is a chemotherapy that helps ward off tumors in many types of cancer, however, it can also have significant side effects, especially kidney toxicity, often leading to acute kidney failure
。 In addition, patients treated with cisplatin often exhibit high levels of neuropathic pain, and a paper published in the Journal of Clinical Investigation titled "Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while.
" Preserving CISPLATIN Antitumor Effects", scientists from the University of Lille II and other institutions in France have identified a new type of drug
that can change the rules of patient treatment.

The researchers said that istradefylline, a drug approved for the treatment of Parkinson's disease, can not only reduce the harmful effects of cisplatin treatment, but also improve its anti-tumor properties, and the results may need to be further confirmed
in clinical trials 。 Cisplatin is often used to treat many types of cancer, including lung, ovarian and testicular cancer, and although researchers have demonstrated its anti-tumor efficacy, cisplatin still promotes side effects, including intense pain (peripheral neuropathy) and kidney damage, which can lead to acute kidney failure in one third of patients.

Itraphyline, a Parkinson's disease drug, may be expected to reduce the side effects
of cisplatin chemotherapy.

Image source: Journal of Clinical Investigation (2022).
DOI:10.
1172/JCI152924

In this study, the researchers identified a novel molecule that reduces the side effects induced by cisplatin therapy and preserves or even enhances its anti-tumor properties
.
The researchers focused on a drug called itrline, which has been approved in the United States and Japan to treat Parkinson's disease, and biologically blocks adenosine receptors
on the cell surface.
Researchers Blum, who specializes in human neurodegenerative diseases, had previously observed an increase in the density of these adenosine receptors in the brains of dementia patients, a phenomenon that is often implicated in the occurrence of these diseases, and interestingly, also observed increases
in adenosine receptor levels in the kidneys of cisplatin-treated patients.

With this in mind, the researchers decided to analyze the effect of itraphylline on mitigating the harmful effects of cisplatin through joint studies, and by experimenting with animal and cell models, the researchers observed the beneficial effects of itraphylline, a molecule that not only reduces kidney damage but also prevents neuropathic pain in the body in mice exposed to
cisplatin.
In addition, cisplatin's ability to reduce tumor growth was also increased in animals treated with itrline, an effect that the researchers subsequently confirmed in cell models
.

Before considering the use of this treatment in cancer patients, the results of the study must first be consolidated by organizing rigorous clinical trials, and the fact that itratechline is now being used to treat another human disease constitutes a very interesting research perspective
.
The researchers say that we already have a large amount of clinical data to reveal that itrlineline is safe, and although clinical trials are necessary to test its efficacy in reducing chemotherapy side effects, the possibility of retargeting treatment may become a potential perspective
for improving patient care in the short term.

In summary, the results of this study support the use of itraphylline as a valuable preventive strategy for the clinical management
of patients receiving cisplatin therapy.
(Biovalley Bioon.
com)

Original source:

Edmone Dewaeles,Kévin Carvalho,Sandy Fellah, et al.
 Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects, Journal of Clinical Investigation (2022).
DOI: 10.
1172/JCI152924